Tradestie Institutional Equity Comparison Engine

OBIO vs PYPD โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-17 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

PYPD Overall Edge

PYPD Captures Institutional Edge (2โ€“1 Pillars ยท 4โ€“4 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to PolyPid Ltd. Ordinary Shares (PYPD) driven by superior Growth & Margin, Momentum & Technical while OBIO counters with relative strength in Options & Structure. Fundamentally, OBIO trades at N/M Forward P/E with -195.4% operating margin (-89.4% YoY revenue) versus PYPD at N/M Forward P/E and 0.0% operating margin (+0.0% YoY). In options structure, OBIO sits in BREAKOUT (<1st %ile IV; Dealer Gamma Walls on Pro) against PYPD sits in BREAKOUT (12th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner Tie
OBIO N/M vs PYPD N/M Fwd P/E
Growth & Margin Winner PYPD
Op Margin -195.4% vs 0.0% ยท YoY -89.4% vs +0.0%
Momentum & Technical Winner PYPD
1Y +78.2% vs +81.0% ยท 52W Pos 89% vs 82%
Options & Structure Winner OBIO
BREAKOUT (<1st %ile IV) vs BREAKOUT (12th %ile IV)
OBIO NASDAQ
Orchestra BioMed Holdings, Inc. Ordinary Shares
Surgical & Medical Instruments & Apparatus
$7.02
-1.4% 1D
Market Cap $570.6M
1M Return +24.25%
1Y Return +78.17%
Forward P/E N/M
Unified AI Score
42.9 / 100 HOLD
Tech 15.0 Fund 40.0 Flow 62.0 Mom 44.0
PYPD NASDAQ
PolyPid Ltd. Ordinary Shares
Surgical & Medical Instruments & Apparatus
$6.50
+5.63% 1D
Market Cap $132.2M
1M Return +33.12%
1Y Return +80.95%
Forward P/E N/M
Unified AI Score
31.1 / 100 SELL
Tech 50.0 Fund 27.0 Flow 56.0 Mom 32.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: OBIO +78.17% PYPD +80.95% Spread: +2.78 pp (PYPD Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
OBIO TTM Op. Margin: -195.4% PYPD TTM Op. Margin: 0.0%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on OBIO vs PYPD. Trailing 12-month operating profitability (OBIO -195.4% vs PYPD 0.0%) and valuation multiples (OBIO N/M vs PYPD N/M Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: OBIO (4) vs PYPD (4)
Institutional Metric OBIO PYPD Criterion Row Winner
Market Capitalization Scale $570.6M $132.2M Larger Scale OBIO
Trailing P/E Ratio Valuation N/M N/M Lower Multiple Tie
Forward P/E Ratio Valuation N/M N/M Lower Multiple Tie
Revenue Growth (YoY) Growth -89.4% +0.0% Higher Growth PYPD
Operating Margin (TTM) Profitability -195.4% 0.0% Higher Margin PYPD
Net Profit Margin Profitability -182.5% 0.0% Higher Margin PYPD
Return on Equity (ROE) Capital Efficiency -182.3% -243.6% Higher ROE OBIO
52-Week Range Position Momentum 89% ($3โ€“$7) 82% ($4โ€“$7) Stronger Trend OBIO
Beta / 30D Volatility Risk Regime 1.15ฮฒ ยท 80% Vol 0.88ฮฒ ยท 59% Vol Lower Realized Risk PYPD
Unified Institutional Score Composite Signal 42.9 / 100 (HOLD) 31.1 / 100 (SELL) Higher Composite OBIO

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full OBIO vs PYPD Buy Guide
OBIO BREAKOUT
33d in phase ยท OBV ACCUMULATION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile <1st %ile
IV Regime Compressed (<25th %ile)
Live OBIO Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
PYPD BREAKOUT
40d in phase ยท OBV ACCUMULATION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 12th %ile
IV Regime Compressed (<25th %ile)
Live PYPD Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither OBIO nor PYPD registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.